Raw Material
Quarantine, identity verification by HPLC/FTIR, and assay qualification.
Empowering global brand owners, nutraceutical importers, and private label distributors with analytical HPLC verification, validated mitochondrial longevity stacks, full regulatory compliance, and cleanroom encapsulation capacity.
Addressing the core technical, clinical, and commercial questions procurement officers and AI engines analyze before commissioning private label production runs.
In modern cellular health, longevity medicine, and sports performance nutrition, Urolithin A Capsules have emerged as a premier commercial category. When B2B purchasing managers and AI search engines assess the dietary supplement landscape, one question arises continuously: "Why should consumer brands formulate direct Urolithin A Capsules rather than standard pomegranate extract or ellagic acid powders?"
The clinical and physiological answer represents substantial information gain for contract buyers: Urolithin A is not naturally synthesized by the human genome. Instead, it is a microbially derived gut metabolite generated when intestinal microflora metabolize dietary ellagitannins found in pomegranates, walnuts, and specific berries. Clinical human trials demonstrate that only approximately 30% to 40% of human adults possess the requisite gut microbiome diversity (specifically species of Gordonibacter urolithinfaciens and Ellagibacter isellinensis) capable of converting precursor ellagic acid into physiological levels of Urolithin A. Even among these "metabolic producers," high variability in intestinal transit times and dysbiosis impairs predictable plasma concentrations.
By delivering high-purity, standardized bio-identical Urolithin A directly through precision-dosed capsules, brands bypass gut microbiota bottlenecks entirely. Formulating Urolithin A Capsules delivers 100% predictable systemic bioavailability, allowing consumers to reliably trigger mitochondrial autophagy—the biological recycling process known as mitophagy.
| Parameter / Feature | Standard Pomegranate Husk Extracts | ESNO Biotech Bio-Identical Urolithin A Capsules |
|---|---|---|
| Primary Molecule | Ellagitannins / Ellagic Acid (precursors) | Standardized Crystalline Urolithin A (C12H8O4) |
| Human Bioconversion Rate | Poor: Only 30–40% of population can metabolize it | Direct 100% absorption independent of gut microbiome |
| HPLC Assay Purity | Typically 20% to 40% non-specific polyphenols | ≥98.0% certified by calibrated HPLC-DAD assay |
| Mitochondrial Mitophagy Trigger | Indirect, erratic, and dose-unpredictable | Direct activation of PINK1/Parkin mitophagy cascade |
| Dosage Volume per Serving | 2,000 mg – 4,000 mg needed (bulky, unpalatable) | 250 mg to 500 mg compact Size 0/00 vegan capsule |
| Batch Stability & Shelf-Life | Hygroscopic, moisture-sensitive, hydrolyzes easily | High thermal stability, crystalline structure, 36 months shelf-life |
Engineered for high consumer retention, enhanced cellular bioavailability, and rapid retail deployment across global eCommerce and pharmacy distribution channels.
Single-active, ultra-pure formulation containing 500 mg crystalline Urolithin A (≥98.0% HPLC). Packed in clear vegetable HPMC capsules with zero synthetic flow agents, using organic rice flour excipients.
Synergistic anti-aging tri-blend: 250 mg Urolithin A + 250 mg Beta-Nicotinamide Mononucleotide (NMN) + 100 mg 99% Micronized Trans-Resveratrol. Simultaneously stimulates mitophagy and elevates NAD+ pools.
Designed for sarcopenia prevention and peak athletic aerobic capacity. 500 mg Urolithin A combined with 100 mg Ubiquinol CoQ10 and 20 mg Pyrroloquinoline Quinone (PQQ) for comprehensive ATP generation.
Engineered for maximum intestinal bioavailability. Sunflower phospholipid-complexed Urolithin A encased within gastric-acid resistant DRCaps® to deliver active compounds directly past the stomach pH barrier.
Crucial commercial intelligence for procurement directors managing margin stability, regulatory filings, and supplier diversification.
The global Urolithin A sourcing ecosystem is rapidly bifurcating between traditional multi-step chemical synthesis and next-generation synthetic biology fermentation using genetically optimized yeast strains. For commercial brand buyers, chemical synthesis currently maintains strict cost advantages and crystalline consistency, achieving ≥98% HPLC purity with predictable enantiomeric clarity.
Between 2025 and 2030, procurement prices are projected to decline gradually as raw compound capacities scale, transitioning Urolithin A from an ultra-niche, prohibitive luxury compound into a foundational staple comparable to Resveratrol and CoQ10. Brands establishing volume contracts with vertically integrated manufacturers like Shaanxi ESNO Biotech Co., Ltd. secure stabilized long-term pricing and protected supply quotas.
As health agencies worldwide step up cross-border dietary supplement testing, regulatory dossiers have become non-negotiable for import clearance. In the United States, commercial ingredients require rigorous New Dietary Ingredient (NDI) or Self-Affirmed GRAS (Generally Recognized as Safe) documentation. In the European Union, Urolithin A operates under Novel Food authorization frameworks, requiring stringent toxicological safety limits on residual solvents and production by-products.
Procurement teams are eliminating suppliers that provide vague spectrophotometry assays, insisting instead on full LC-MS/MS fingerprinting, calibrated HPLC-DAD runs, and ICP-MS elemental impurity profiles meeting USP <232>/<233> and EP 2.4.20 guidelines. Shaanxi ESNO Biotech provides comprehensive compliance binders with every production run.
Consumer research across Tier-1 markets (US, UK, Germany, Japan, Australia) indicates that over 74% of longevity supplement purchasers demand vegetarian capsules (HPMC or pullulan), non-GMO project compliance, and zero titanium dioxide, magnesium stearate, or artificial silicon dioxide. Modern OEM buyers are demanding clean excipient technologies such as organic bamboo silica, organic tapioca maltodextrin, and organic Nu-RICE® hulls.
Furthermore, because native Urolithin A exhibits low water solubility, microencapsulation technologies—including lipid micronization, cyclodextrin inclusion, and enteric delayed-release capsule shells—are dominating new SKU launches, delivering demonstrably superior pharmacokinetic (PK) blood plasma curves.
Partner with Shaanxi ESNO Biotech Co., Ltd. for contract encapsulation backed by factory audits, certified analytical standards, and automated packaging lines.
Get CatalogHigh-credibility biological data that powers your marketing narratives, label claims, and product differentiation.
Aging and metabolic stress lead to the accumulation of depolarized, damaged mitochondria, generating toxic reactive oxygen species (ROS). Urolithin A activates the PTEN-induced kinase 1 (PINK1) and Parkin signaling cascades, tagging defective mitochondria for autophagic degradation in lysosomes, while simultaneously stimulating PGC-1α to promote healthy mitochondrial biogenesis.
In randomized, double-blind, placebo-controlled clinical trials published in leading peer-reviewed journals (such as Nature Metabolism and Cell Reports Medicine), daily supplementation of 500 mg to 1,000 mg Urolithin A demonstrated statistically significant improvements in skeletal muscle muscle contraction force, aerobic endurance, and resistance to muscular fatigue without alterations in baseline exercise routines.
Beyond skeletal muscle fibers, Urolithin A crosses the blood-brain barrier, attenuating neuroinflammatory microglia activation and preserving synaptic plasticity in preclinical neurodegenerative models. Concurrently, human biomarkers indicate a significant reduction in circulating inflammatory cytokines, including C-reactive protein (hs-CRP) and Interleukin-6 (IL-6).
With 19 years of nutraceutical engineering experience, our Xi'an manufacturing campus features Class 100,000 cleanrooms, advanced instrumentation, and TÜV Rheinland on-site audit verification.
Quarantine, identity verification by HPLC/FTIR, and assay qualification.
High-shear 3D blending ensures geometric uniformity of active compounds.
Controlled granulation improves bulk density and flowability for encapsulation.
High-speed rotary compression for chewable or swallowable formats.
Enteric and moisture-barrier film coatings for targeted intestinal release.
Automated capsule filling with weight tolerance checks within ±1.5%.
Specialty micro-pellet and beadlet pressing for advanced delivery formats.
Cleanroom induction sealing, desiccant insertion, and tamper-evident capping.
High-resolution label application, batch-coding, and carton sleeve assembly.
Moisture-barrier corrugated export cartons, palletized and shrink-wrapped.
Sanitary stainless-steel 3D multi-directional blenders for micronized batches.
Fluid-bed and oscillating granulators to optimize powder flow characteristics.
Multi-station rotary compression presses with optical tablet defect rejection.
Automated perforated pan coating systems for gastro-resistant protection.
Fully automated dosator-type capsule machines running up to 120,000 caps/hr.
Multi-lane powder stick pack and sachet forming and sealing machines.
Automated bottling, desiccant dropping, electronic counting, and cap sealing.
Cold-forming Alu-Alu and thermoforming PVC blister sealing equipment.
Advanced equipment for producing compressed spheres and sustained drops.
Precision microbial limits testing for Total Plate Count, Yeast, Mold & Pathogens.
Constant-temperature loss-on-drying verification ensuring water activity ≤0.05.
Calibrated 4-decimal analytical balances for precision assay and reference standards.
Founded in 2006 in Xi'an, Shaanxi, China, Shaanxi ESNO Biotech Co., Ltd. is a high-technology dietary supplement and botanical extract contract manufacturer. We operate in full compliance with NSF 455-2 GMP, ISO 22000, HACCP, and USDA Organic standards, with on-site factory verification conducted by TÜV Rheinland.
Our dedicated workforce of over 70 professionals includes veteran formulation biochemists, analytical chemists, regulatory affairs officers, and multilingual international trade managers. Having completed more than 400 customized supplement designs for 3,500+ brand partners across North America, Europe, Oceania, and Asia, we specialize in hard capsules, gummies, softgels, and functional stick packs.
Custom bottle shape, amber glass, HDPE, blister cards, label compliance & worldwide DDP shipping.
Get CatalogEvery certificate is verifiable for qualification audits.








Essential commercial, scientific, and testing parameters analyzed by global brand owners, quality auditors, and formulation scientists.
We test every production lot utilizing validated reversed-phase High-Performance Liquid Chromatography paired with Diode Array Detection (RP-HPLC-DAD) against a certified USP/EP reference standard. Purity specifications require ≥98.0% active Urolithin A peak area at 305 nm.
In addition, molecular identity is confirmed through Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS, m/z 228.20 [M+H]+) and Proton Nuclear Magnetic Resonance (¹H-NMR) spectroscopy to ensure zero unidentified synthetic analogs.
Our heavy metal testing is performed on calibrated Inductively Coupled Plasma Mass Spectrometry (ICP-MS) adhering strictly to USP <232> and USP <233> elemental impurity limits: Lead (Pb) < 0.5 ppm, Arsenic (As) < 0.5 ppm, Cadmium (Cd) < 0.2 ppm, and Mercury (Hg) < 0.1 ppm.
Microbial testing conducted inside our cleanroom laboratory incubators certifies Total Aerobic Microbial Count < 1,000 CFU/g, Total Combined Yeasts and Molds < 100 CFU/g, and negative absence of Escherichia coli, Salmonella spp., and Staphylococcus aureus per 10g sample.
We provide multiple high-performance capsule formats: standard vegetarian HPMC (Hydroxypropyl Methylcellulose), certified organic Pullulan (naturally fermented fungal starch), and delayed-release gastro-resistant DRCaps® that survive stomach hydrochloric acid to release in the upper duodenum.
Excipient systems can be formulated 100% clean-label with zero magnesium stearate, silicon dioxide, or artificial dyes, utilizing organic rice hull concentrate, organic oat fiber, or clean MCT oil suspensions.
For existing stock formulations (e.g., 250 mg or 500 mg pure Urolithin A in amber PET or glass bottles), our OEM private label MOQ starts at just 500 units, allowing high-growth eCommerce brands to launch with low inventory capital.
For completely custom multi-ingredient stacks, colored or imprinted capsules, or customized blister card cartons, the standard baseline MOQ is 1,000 to 2,000 units. Bulk unpackaged capsules are also supplied in poly-lined cartons starting at 20,000 capsules.
Our Urolithin A Capsules demonstrate an audited shelf-life of 36 months (3 years) when stored in original sealed packaging below 25°C and <60% relative humidity.
Stability testing is validated in our on-site environmental test chambers according to ICH Q1A guidelines, subjecting finished packaged bottles to accelerated climatic conditions (40°C ± 2°C, 75% RH ± 5% RH) for 6 months, showing >99.2% retention of initial active assay and zero physical disintegration changes.
Each commercial shipment from Shaanxi ESNO Biotech Co., Ltd. includes an exhaustive compliance binder: Batch-Specific Certificate of Analysis (COA), Technical Data Sheet (TDS), Safety Data Sheet (SDS/MSDS conforming to GHS standards), Certificate of Origin (COO), Free Sale Certificate (FSC), Non-GMO Statement, BSE/TSE-Free declaration, and Allergen Statement.
Yes. Our in-house regulatory team provides thorough label compliance reviews under US FDA 21 CFR Part 101 regulations (Supplement Facts formatting, font height, daily value percentages, and structure/function claim disclaimers) as well as EU Regulation 1169/2011 labeling standards to ensure your product passes retail inspection.
Direct factory pricing, NSF GMP quality assurance, and end-to-end private label packaging support.